Christopher Marai
Stock Analyst at Nomura
(2.48)
# 2,247
Out of 4,842 analysts
33
Total ratings
51.61%
Success rate
10.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Marai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $360 → $960 | $7.23 | +13,178.01% | 2 | Jun 4, 2020 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $29 → $33 | $45.75 | -27.87% | 2 | May 11, 2020 | |
| SLDB Solid Biosciences | Maintains: Buy | $150 → $90 | $3.26 | +2,660.74% | 5 | May 8, 2020 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Reduce | $74 | $285.81 | -74.11% | 4 | Apr 14, 2020 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $37 → $16 | $2.73 | +486.08% | 2 | Mar 30, 2020 | |
| BIIB Biogen | Maintains: Buy | $320 → $392 | $127.53 | +207.38% | 7 | Feb 7, 2020 | |
| BYSI BeyondSpring | Initiates: Buy | $34 | $1.66 | +1,948.19% | 1 | Jan 10, 2020 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $205 → $230 | $37.23 | +517.78% | 3 | Feb 28, 2019 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $22 → $12 | $10.12 | +18.58% | 3 | Dec 17, 2018 | |
| PRTA Prothena Corporation | Maintains: Buy | $87 → $19 | $4.60 | +313.04% | 2 | Apr 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $43 | $1.41 | +2,949.65% | 2 | Sep 6, 2017 |
Corbus Pharmaceuticals Holdings
Jun 4, 2020
Maintains: Buy
Price Target: $360 → $960
Current: $7.23
Upside: +13,178.01%
Protagonist Therapeutics
May 11, 2020
Maintains: Buy
Price Target: $29 → $33
Current: $45.75
Upside: -27.87%
Solid Biosciences
May 8, 2020
Maintains: Buy
Price Target: $150 → $90
Current: $3.26
Upside: +2,660.74%
Alnylam Pharmaceuticals
Apr 14, 2020
Maintains: Reduce
Price Target: $74
Current: $285.81
Upside: -74.11%
Voyager Therapeutics
Mar 30, 2020
Maintains: Buy
Price Target: $37 → $16
Current: $2.73
Upside: +486.08%
Biogen
Feb 7, 2020
Maintains: Buy
Price Target: $320 → $392
Current: $127.53
Upside: +207.38%
BeyondSpring
Jan 10, 2020
Initiates: Buy
Price Target: $34
Current: $1.66
Upside: +1,948.19%
Sarepta Therapeutics
Feb 28, 2019
Maintains: Buy
Price Target: $205 → $230
Current: $37.23
Upside: +517.78%
Syndax Pharmaceuticals
Dec 17, 2018
Maintains: Buy
Price Target: $22 → $12
Current: $10.12
Upside: +18.58%
Prothena Corporation
Apr 24, 2018
Maintains: Buy
Price Target: $87 → $19
Current: $4.60
Upside: +313.04%
Sep 6, 2017
Maintains: Buy
Price Target: $49 → $43
Current: $1.41
Upside: +2,949.65%